Imfinzi-话题@MedSci

#Imfinzi#

17篇内容 | 1290人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1416503, encodeId=dc98141650306, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=Imfinzi联合tremelimumab在肝癌中显示出延长OS的益处, objectType=article, longId=294612, objectId=c7ac294612ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7ac294612ce, replyNumber=0, likeNumber=75, createdTime=2022-01-26, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7ac294612ce, moduleTitle=Imfinzi联合tremelimumab在肝癌中显示出延长OS的益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7ac294612ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416502, encodeId=59871416502ae, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率, objectType=article, longId=218686, objectId=4c14218686ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c14218686ce, replyNumber=0, likeNumber=75, createdTime=2021-10-17, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c14218686ce, moduleTitle=Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c14218686ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416501, encodeId=541e1416501ce, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=NMPA批准阿斯利康的小细胞肺癌免疫疗法Imfinzi, objectType=article, longId=214501, objectId=742d214501d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=742d214501d7, replyNumber=0, likeNumber=75, createdTime=2021-07-22, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=742d214501d7, moduleTitle=NMPA批准阿斯利康的小细胞肺癌免疫疗法Imfinzi, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=742d214501d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416500, encodeId=5b6c1416500f1, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=阿斯利康在美国撤销Imfinzi的晚期膀胱癌适应症, objectType=article, longId=207493, objectId=cfff20e493bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfff20e493bc, replyNumber=0, likeNumber=60, createdTime=2021-02-24, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfff20e493bc, moduleTitle=阿斯利康在美国撤销Imfinzi的晚期膀胱癌适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfff20e493bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416499, encodeId=e1d41416499dc, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=阿斯利康的Imfinzi无法提高头颈癌患者的总体生存率, objectType=article, longId=207015, objectId=bc7b20e0156f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7b20e0156f, replyNumber=0, likeNumber=72, createdTime=2021-02-11, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7b20e0156f, moduleTitle=阿斯利康的Imfinzi无法提高头颈癌患者的总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7b20e0156f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416498, encodeId=d7f91416498c3, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=欧盟批准Imfinzi（durvalumab）一线治疗广泛期小细胞肺癌, objectType=article, longId=200402, objectId=25b120040271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b120040271, replyNumber=0, likeNumber=66, createdTime=2020-09-09, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b120040271, moduleTitle=欧盟批准Imfinzi（durvalumab）一线治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25b120040271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416497, encodeId=d8b2141649edd, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌, objectType=article, longId=199855, objectId=787719985534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=787719985534, replyNumber=0, likeNumber=70, createdTime=2020-08-24, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=787719985534, moduleTitle=PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=787719985534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416496, encodeId=a2851416496f0, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗, objectType=article, longId=191241, objectId=eff619124151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eff619124151, replyNumber=0, likeNumber=63, createdTime=2020-04-03, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eff619124151, moduleTitle=FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eff619124151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416495, encodeId=bf5e14164956f, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查, objectType=article, longId=183990, objectId=e516183990ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e516183990ae, replyNumber=0, likeNumber=86, createdTime=2019-12-04, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e516183990ae, moduleTitle=FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e516183990ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416494, encodeId=dc3f1416494d8, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=针对广泛期小细胞肺癌，免疫治疗药物Imfinzi显著改善生存获益和持久疗效, objectType=article, longId=179249, objectId=c3431e924935, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3431e924935, replyNumber=0, likeNumber=66, createdTime=2019-09-12, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3431e924935, moduleTitle=针对广泛期小细胞肺癌，免疫治疗药物Imfinzi显著改善生存获益和持久疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3431e924935)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416493, encodeId=e8e71416493b8, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定, objectType=article, longId=175359, objectId=a0671e535994, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0671e535994, replyNumber=0, likeNumber=60, createdTime=2019-07-14, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0671e535994, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0671e535994)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416492, encodeId=e8871416492af, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, objectType=article, longId=174364, objectId=c1da1e436402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e436402, replyNumber=0, likeNumber=75, createdTime=2019-06-29, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e436402, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e436402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416491, encodeId=3bcb141649137, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, objectType=article, longId=149623, objectId=297e149623e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297e149623e6, replyNumber=0, likeNumber=69, createdTime=2018-09-27, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297e149623e6, moduleTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=297e149623e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416490, encodeId=2ec11416490cb, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=Advaxis的axalimogene filolisbac与阿斯利康Imfinzi的联合研究取得进展, objectType=article, longId=144570, objectId=79031445e078, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79031445e078, replyNumber=0, likeNumber=80, createdTime=2018-07-18, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79031445e078, moduleTitle=Advaxis的axalimogene filolisbac与阿斯利康Imfinzi的联合研究取得进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79031445e078)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416489, encodeId=0e0e14164894f, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=Axalimogene Filolisbac与Imfinzi组合研究中出现致死病例, objectType=article, longId=132573, objectId=8d291325e35e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d291325e35e, replyNumber=0, likeNumber=69, createdTime=2018-03-17, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d291325e35e, moduleTitle=Axalimogene Filolisbac与Imfinzi组合研究中出现致死病例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d291325e35e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416488, encodeId=118f141648822, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=阿斯利康旗下的Imfinzi获得FDA批准用于肺癌治疗, objectType=article, longId=130696, objectId=3cf91306968b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cf91306968b, replyNumber=0, likeNumber=74, createdTime=2018-02-28, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cf91306968b, moduleTitle=阿斯利康旗下的Imfinzi获得FDA批准用于肺癌治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cf91306968b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416487, encodeId=c3c1141648e39, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, objectTitle=PD-1/PD-L1抑制剂市场再添一员！阿斯利康PD-L1抑制剂Imfinzi获FDA加速批准, objectType=article, longId=101079, objectId=78e61010e913, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78e61010e913, replyNumber=0, likeNumber=77, createdTime=2017-05-12, rootId=0, userName=swallow, userId=34be3191285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78e61010e913, moduleTitle=PD-1/PD-L1抑制剂市场再添一员！阿斯利康PD-L1抑制剂Imfinzi获FDA加速批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78e61010e913)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Imfinzi

2020-05-29

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

Imfinzi联合tremelimumab在肝癌中显示出延长OS的益处

2022-01-26

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率

2021-10-17

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

NMPA批准阿斯利康的小细胞肺癌免疫疗法Imfinzi

2021-07-22

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

阿斯利康在美国撤销Imfinzi的晚期膀胱癌适应症

2021-02-24

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

阿斯利康的Imfinzi无法提高头颈癌患者的总体生存率

2021-02-11

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

欧盟批准Imfinzi（durvalumab）一线治疗广泛期小细胞肺癌

2020-09-09

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌

2020-08-24

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗

2020-04-03

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查

2019-12-04

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

针对广泛期小细胞肺癌，免疫治疗药物Imfinzi显著改善生存获益和持久疗效

2019-09-12

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定

2019-07-14

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点

2019-06-29

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌

2018-09-27

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

Advaxis的axalimogene filolisbac与阿斯利康Imfinzi的联合研究取得进展

2018-07-18

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

Axalimogene Filolisbac与Imfinzi组合研究中出现致死病例

2018-03-17

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

阿斯利康旗下的Imfinzi获得FDA批准用于肺癌治疗

2018-02-28

swallow (审核中...)

前往app查看评论内容

#Imfinzi#

PD-1/PD-L1抑制剂市场再添一员！阿斯利康PD-L1抑制剂Imfinzi获FDA加速批准

2017-05-12

科室
- - 订阅+
  - 更多科室
工具
服务